Interpace Biosciences

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. The company is headquartered in Parsippany, New Jersey and currently employs 111 full-time employees. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The firm develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. The company has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.